๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Relapsed or Refractory Multiple Myeloma

Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma NCT07772024Phase 31 site๐Ÿ“ Miami CellCentric Ltd. ยท Tests: InoPd, Investigator's choice of SAT A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments NCT05714839Phase 1, Phase 244 sites๐Ÿ“ Bullhead City๐Ÿ“ Los Angeles๐Ÿ“ Pembroke Pines GlaxoSmithKline ยท Tests: Belantamab, Belantamab mafodotin, Pomalidomide, Dexamethasone Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma NCT06375044Phase 116 sites๐Ÿ“ Phoenix๐Ÿ“ Orange๐Ÿ“ Jacksonville Jiangsu Simcere Pharmaceutical Co., Ltd. ยท Tests: SIM0500 A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma. NCT06232096Phase 1, Phase 21 site๐Ÿ“ Beijing Beijing Mabworks Biotech Co., Ltd. ยท Tests: MBS314 Injection A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma NCT07637578Phase 26 sites๐Ÿ“ Denver๐Ÿ“ Denver๐Ÿ“ Columbia SCRI Development Innovations, LLC ยท Tests: Elranatamab, Tocilizumab A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma NCT07105059Phase 17 sites๐Ÿ“ Basking Ridge๐Ÿ“ Middletown๐Ÿ“ Montvale Memorial Sloan Kettering Cancer Center ยท Tests: Teclistamab, Mezigdomide Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma NCT05972135Phase 217 sites๐Ÿ“ Tucson๐Ÿ“ Denver๐Ÿ“ Denver SCRI Development Innovations, LLC ยท Tests: Teclistamab, Talquetamab, Tocilizumab, Oral Dexamethasone A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients NCT06508983Phase 312 sites๐Ÿ“ Beijing๐Ÿ“ Guangzhou๐Ÿ“ Guangzhou Hangzhou Sumgen Biotech Co., Ltd. ยท Tests: SG301 Injection, SG301 placebo, pomalidomide, dexamethasone A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma NCT07609030NA1 site๐Ÿ“ Columbus Ohio State University Comprehensive Cancer Center ยท Tests: Biospecimen Collection, Cognitive Intervention, Electronic Health Record Review, Survey Administration Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma NCT05976555Phase 11 site๐Ÿ“ Milwaukee Medical College of Wisconsin ยท Tests: BCMA-TGFฮฒ CAR-T cells (0.50 x 10^6 cells/kg), BCMA-TGFฮฒ CAR-T cells (0.75 x10^6 cells/kg), BCMA-TGFฮฒ CAR-T cells (1 x 1โ€ฆ A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma NCT07116616Phase 1, Phase 210 sites๐Ÿ“ Birmingham๐Ÿ“ San Francisco๐Ÿ“ Atlanta ModernaTX, Inc. ยท Tests: mRNA-2808 Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dualโ€ฆ Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration NCT07003555Phase 11 site๐Ÿ“ Shanghai Beijing GoBroad Hospital ยท Tests: Dual-targeting BCMA-CD19 CAR-T cell infusion MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) NCT06152575Phase 3270 sites๐Ÿ“ Mobile๐Ÿ“ Goodyear๐Ÿ“ Beverly Hills Pfizer ยท Tests: Elranatamab, Elotuzumab, Pomalidomide, Dexamethasone, Bortezomib LMY-920 for Treatment of Relapsed or Refractory Myeloma NCT05546723Phase 11 site๐Ÿ“ Cleveland Luminary Therapeutics ยท Tests: Autologous CAR-T cell therapy expressing the BAFF-ligand. A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma NCT06121843Phase 119 sites๐Ÿ“ Birmingham๐Ÿ“ Phoenix๐Ÿ“ Duarte Juno Therapeutics, Inc., a Bristol-Myers Squibb Company ยท Tests: BMS-986393, Alnuctamab, Mezigdomide, Iberdomide, Elranatamab A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma NCT06574568Phase 112 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Foshan Excyte Biopharma Ltd ยท Tests: YKST02 A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma NCT05299424Phase 1, Phase 21 site๐Ÿ“ Beijing Keymed Biosciences Co.Ltd ยท Tests: CM336_group 1, CM336_group 2a, CM336_group 2b, CM336_group 3a, CM336_group 3b BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma NCT04162353Phase 12 sites๐Ÿ“ Shenzhen๐Ÿ“ Chengdu iCell Gene Therapeutics ยท Tests: BCMA-CD19 cCAR T cells A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma NCT07579234Phase 31 site๐Ÿ“ Tianjing Shandong New Time Pharmaceutical Co., LTD ยท Tests: F182112 single-agent, Pomalidomide + Bortezomib + Dexamethasone (PVd) or Selinexor + Bortezomib + Dexamethasone (SVd) APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma NCT04657861EARLY Phase 11 site๐Ÿ“ Hangzhou Zhejiang University ยท Tests: APRIL CAR-T cells Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma NCT06896916Phase 127 sites๐Ÿ“ Beverly Hills๐Ÿ“ Denver๐Ÿ“ St Louis AbbVie ยท Tests: Etentamig, Iberdomide Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma NCT05565807Phase 1, Phase 24 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Guangzhou Zhejiang ACEA Pharmaceutical Co. Ltd. ยท Tests: STI-6129 Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse NCT06948084Phase 231 sites๐Ÿ“ Coeur d'Alene๐Ÿ“ Post Falls๐Ÿ“ Sandpoint National Cancer Institute (NCI) ยท Tests: Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluroโ€ฆ Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma NCT07479979Phase 1, Phase 21 site๐Ÿ“ Madison Natalie Callander ยท Tests: Selinexor, Carfilzomib, Isatuximab, Isatuximab SC Wearable Injection System, Dexamethasone A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 NCT07623798Phase 31 site๐Ÿ“ Shanghai Innovent Biologics (Suzhou) Co. Ltd. ยท Tests: Pomalidomide Capsules, Bortezomib for Injection, Daratumumab Injection (Subcutaneous Injection), IBI3003, Selinexor Tabโ€ฆ Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration NCT07003568Phase 11 site๐Ÿ“ Shanghai Beijing GoBroad Hospital ยท Tests: Dual-targeting BCMA-GPRC5D CAR-T cell infusion A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM) NCT07771803EARLY Phase 11 site๐Ÿ“ Camden Roger Strair ยท Tests: Soursop tea A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) NCT07222761Phase 344 sites๐Ÿ“ Atlanta๐Ÿ“ New York๐Ÿ“ Columbus Regeneron Pharmaceuticals ยท Tests: Linvoseltamab, Carfilzomib, Daratumumab, Dexamethasone, Pomalidomide A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma NCT05650632Phase 146 sites๐Ÿ“ Phoenix๐Ÿ“ Springdale๐Ÿ“ Aurora AbbVie ยท Tests: Etentamig (ABBV-383)
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy